Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-04-07
Butterfly Network, Inc.
Butterfly sells handheld semiconductor-based ultrasound probes plus cloud workflow software, AI tools, and licensing capabilities for clinicians, health systems, educators, and partners.
ai healthcare medical devices semiconductors software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Handheld ultrasound with real platform optionality
The upside case rests on more than selling probes: the business must convert workflow software, regulated trust, and embedded licensing into repeatable revenue. If that mix shift happens, a 2-3x equity outcome by 2031 is plausible; if not, valuation compresses toward device peers.

Analysis

Thesis
Butterfly can turn a differentiated handheld-ultrasound product into a regulated workflow and embedded-imaging platform; if Embedded, enterprise software, and HomeCare become repeatable instead of bespoke, growth can outpace normal device peers while staying within a credible medtech valuation frame.
Last Economy Alignment
AI should widen handheld ultrasound use by lowering training and workflow friction, and Butterfly owns the chip and hospital workflow links. The cap is that regulation and large incumbent bundling still limit value capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.6x (from 5 most recent analyses)
Reasoning
This is a real operating business with improving gross margin and a credible path from device vendor toward workflow and licensing. The upside comes from mix shift, not just more probes. I do not underwrite a pure-software rerating because hospitals buy carefully, regulation slows expansion, and larger imaging vendors can still bundle against Butterfly.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is that Butterfly proves the category but not the platform. Core handheld demand can grow while Embedded, HomeCare, and developer tools stay too bespoke to change the mix, leaving the company as a subscale device name with a still-rich valuation, exposed to hospital budget timing, TSMC dependence, and larger imaging vendors bundling handheld ultrasound into broader enterprise contracts.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.42
They own the handheld ultrasound chip and the hospital workflow links around it, so cheaper AI should make scanning easier and widen who can use the device. The risk is that bigger imaging companies bundle similar tools before Butterfly turns its chip, cloud, and developer surface into a true platform.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$5.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case